[go: up one dir, main page]

MX2017016439A - Composicion farmaceutica oftalmologica. - Google Patents

Composicion farmaceutica oftalmologica.

Info

Publication number
MX2017016439A
MX2017016439A MX2017016439A MX2017016439A MX2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A MX 2017016439 A MX2017016439 A MX 2017016439A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
therapeutically active
solid carrier
ophthalmological
woven
Prior art date
Application number
MX2017016439A
Other languages
English (en)
Other versions
MX376622B (es
Inventor
Kalkbrenner Hans
Original Assignee
Contipro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contipro As filed Critical Contipro As
Publication of MX2017016439A publication Critical patent/MX2017016439A/es
Publication of MX376622B publication Critical patent/MX376622B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para el tratamiento o prevención de enfermedades o trastornos oftalmológicos, en donde la composición farmacéutica comprende un portador sólido en forma de un material no tejido o tejido hecho de fibras solubles en agua y por lo menos un agente terapéuticamente activo, en donde el portador sólido es impregnado con por lo menos el agente terapéuticamente activo, en donde el portador sólido se desintegra fácilmente tras el contacto con el ojo. También está comprendida esta composición para el uso en el tratamiento o prevención de condiciones oftalmológicas y el uso de los materiales no tejidos/tejidos descritos en este documento como portadores para por lo menos un agente terapéuticamente activo en una composición farmacéutica oftalmológica.
MX2017016439A 2015-06-26 2016-06-24 Composicion farmaceutica oftalmologica. MX376622B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15173997.6A EP3108874A1 (en) 2015-06-26 2015-06-26 Ophthalmologic pharmaceutical composition
PCT/EP2016/064653 WO2016207340A1 (en) 2015-06-26 2016-06-24 Ophthalmologic pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2017016439A true MX2017016439A (es) 2018-08-16
MX376622B MX376622B (es) 2025-03-07

Family

ID=53510642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016439A MX376622B (es) 2015-06-26 2016-06-24 Composicion farmaceutica oftalmologica.

Country Status (12)

Country Link
US (1) US20180296473A1 (es)
EP (2) EP3108874A1 (es)
JP (1) JP6918711B2 (es)
KR (1) KR20180021065A (es)
DK (1) DK3313370T3 (es)
ES (1) ES2864638T3 (es)
HU (1) HUE053974T2 (es)
MX (1) MX376622B (es)
MY (1) MY193529A (es)
PL (1) PL3313370T3 (es)
RU (1) RU2734344C2 (es)
WO (1) WO2016207340A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307158B6 (cs) * 2016-12-23 2018-02-07 Contipro A.S. Oftalmologický prostředek
KR102090736B1 (ko) * 2018-05-18 2020-04-23 서울대학교산학협력단 담체 복합체 및 이를 포함하는 약학 조성물
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
KR20240040272A (ko) * 2022-09-21 2024-03-28 동국대학교 산학협력단 약물을 담지한 동결건조 히알루론산을 포함하는 점막 투여용 약물 전달체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075527A (en) * 1960-06-02 1963-01-29 Chemway Corp Sterile medicated strips
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
DE69840495D1 (de) * 1997-02-20 2009-03-12 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
EP1539193A4 (en) * 2002-07-03 2010-05-05 Pericor Science Inc HYALURONIC ACID COMPOSITIONS AND METHODS OF USE
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7323425B2 (en) * 2004-08-27 2008-01-29 Stony Brook Technology And Applied Research Crosslinking of hyaluronan solutions and nanofiberous membranes made therefrom
WO2006028110A1 (ja) 2004-09-07 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 水溶性ヒアルロン酸修飾物の製造方法
CN1757414A (zh) * 2005-09-09 2006-04-12 中国海洋大学 一种治疗眼表疾病的载药可视多糖膜片的制造方法
US8979931B2 (en) * 2006-12-08 2015-03-17 DePuy Synthes Products, LLC Nucleus replacement device and method
US20130136784A1 (en) * 2007-10-11 2013-05-30 Robert J. Staab Methods for delivery of medication using dissolvable devices
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
RU2458709C1 (ru) * 2010-12-28 2012-08-20 Общество с ограниченной ответственностью "НПО ЛИОМАТРИКС" Биопластический материал
CZ20101001A3 (cs) * 2010-12-31 2012-02-08 Cpn S.R.O. Hyaluronová vlákna, zpusob jejich prípravy a použití
WO2013171764A2 (en) * 2012-04-30 2013-11-21 Rubicon Research Private Limited Ophthalmic formulations

Also Published As

Publication number Publication date
EP3313370A1 (en) 2018-05-02
EP3108874A1 (en) 2016-12-28
JP6918711B2 (ja) 2021-08-11
KR20180021065A (ko) 2018-02-28
WO2016207340A1 (en) 2016-12-29
MX376622B (es) 2025-03-07
JP2018518514A (ja) 2018-07-12
PL3313370T3 (pl) 2021-10-25
US20180296473A1 (en) 2018-10-18
RU2018102746A3 (es) 2019-11-29
HUE053974T2 (hu) 2021-07-28
MY193529A (en) 2022-10-18
ES2864638T3 (es) 2021-10-14
EP3313370B1 (en) 2020-12-30
RU2734344C2 (ru) 2020-10-15
RU2018102746A (ru) 2019-07-29
DK3313370T3 (da) 2021-03-29

Similar Documents

Publication Publication Date Title
MX2017016439A (es) Composicion farmaceutica oftalmologica.
CO2019008487A2 (es) Compuesto de quinazolina
MX2024000349A (es) Compuestos y usos de los mismos.
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
WO2014179568A3 (en) Two-layer ocular implant
EP4324454A3 (en) Cross-linking agents and associated methods
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
CL2014002918A1 (es) Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras.
CR20190201A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO7240418A2 (es) Apósito con una liberación prolongada de agentes activos
MX2024006768A (es) Compuestos y usos de los mismos.
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX2015007824A (es) Formulaciones parasiticidas transdermicas.
CO6761349A2 (es) Proteína antimicrobiana
CO2019000178A2 (es) Artículo absorbente con una composición de aceite y un estrato protector de aceite
MX2013002579A (es) Compuesto de quinoxalina.
MX2020011536A (es) Deposito de liquido para liberacion sostenida no invasiva de agentes al ojo.
IL251555A0 (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
CO2019008657A2 (es) Composición intranasal que comprende betahistina

Legal Events

Date Code Title Description
FG Grant or registration